PMID- 30154642
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220321
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 12
DP  - 2018
TI  - Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal 
      vein occlusion.
PG  - 1465-1470
LID - 10.2147/OPTH.S162019 [doi]
AB  - PURPOSE: The aim of this study was to evaluate the effect of initial intravitreal 
      ranibizumab injection on visual acuity (VA) and central macular thickness (CMT) 
      for the treatment of macular edema (ME) with and without serous retinal 
      detachment (SRD) secondary to branch retinal vein occlusion (BRVO). MATERIALS AND 
      METHODS: Fifty-two BRVO eyes, treated with intravitreal ranibizumab injection for 
      ME with and without SRD, were retrospectively reviewed. Patients were divided 
      into two groups according to spectral domain optical coherence tomography 
      (SD-OCT). The efficacy of intravitreal ranibizumab injection at first month was 
      assessed by analyzing the change in best-corrected VA and reduction in CMT with 
      SD-OCT. RESULTS: There were 21 patients with SRD and 31 patients with only CME 
      (no-SRD). CMT was significantly greater in the SRD group than in the CME group 
      (451+/-62.2 microm vs 383.5+/-37.2 microm, respectively, P<0.05). After initial intravitreal 
      ranibizumab injection, mean VA improved from 0.87+/-0.26 logarithm of the minimum 
      angle of resolution (LogMAR) to 0.54+/-0.27 LogMAR (P<0.01) and CMT decreased from 
      451+/-62.2 microm to 379.3+/-58.6 microm (P<0.001) in the SRD group. In the no-SRD group, 
      mean VA improved from 0.69+/-0.25 LogMAR to 0.44+/-0.25 LogMAR (P<0.001) and the CMT 
      decreased from 383.5+/-37.2 microm to 337.7+/-39.4 microm (P<0.001) at the first month visit. 
      Eyes with SRD revealed better anatomic results and greater reduction of CMT after 
      intravitreal ranibizumab injection (P<0.01). CONCLUSION: VA and CMT can be 
      improved by intravitreal ranibizumab injection in BRVO patients with and without 
      SRD. However, more marked improvement in macular morphology was achieved in 
      patients with SRD than those without SRD.
FAU - Dogan, Emine
AU  - Dogan E
AD  - Department of Ophthalmology, Sakarya University Medical Education and Research 
      Hospital, Sakarya, Turkey.
FAU - Sever, Ozkan
AU  - Sever O
AD  - Department of Ophthalmology, Namik Kemal University School of Medicine, Namik 
      Kemal University, Tekirdag, Turkey, sever_ozkan@hotmail.com.
FAU - Koklu Cakir, Burcin
AU  - Koklu Cakir B
AD  - Department of Ophthalmology, Sakarya University Medical Education and Research 
      Hospital, Sakarya, Turkey.
FAU - Celik, Erkan
AU  - Celik E
AD  - Department of Ophthalmology, Sakarya University Medical Education and Research 
      Hospital, Sakarya, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20180817
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC6103606
OTO - NOTNLM
OT  - ranibizumab
OT  - serous detachment
OT  - vein occlusion
COIS- Disclosure The authors have no financial or proprietary interest in any product, 
      method, or material described herein, and report no conflicts of interest in this 
      work.
EDAT- 2018/08/30 06:00
MHDA- 2018/08/30 06:01
PMCR- 2018/08/17
CRDT- 2018/08/30 06:00
PHST- 2018/08/30 06:00 [entrez]
PHST- 2018/08/30 06:00 [pubmed]
PHST- 2018/08/30 06:01 [medline]
PHST- 2018/08/17 00:00 [pmc-release]
AID - opth-12-1465 [pii]
AID - 10.2147/OPTH.S162019 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2018 Aug 17;12:1465-1470. doi: 10.2147/OPTH.S162019. eCollection 
      2018.